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Ubiquitination regulates a host of cellular processes by labeling proteins for degradation, but also by
functioning as a regulatory, nonproteolytic posttranslational modification. Proteome-wide strategies
to monitor changes in ubiquitination profiles are important to obtain insight into the various cellular
functions of ubiquitination. Here we describe generation of stable cell lines expressing a tandem
hexahistidine-biotin tag (HB-tag) fused to ubiquitin for two-step purification of the ubiquitinated
proteome under fully denaturing conditions. Using this approach we identified 669 ubiquitinated proteins
from HeLa cells, including 44 precise ubiquitin attachment sites on substrates and all seven possible
ubiquitin chain-linkage types. To probe the dynamics of ubiquitination in response to perturbation of
the ubiquitin/proteasome pathway, we combined ubiquitin profiling with quantitative mass spectrometry
using the stable isotope labeling with amino acids in cell culture (SILAC) strategy. We compared
untreated cells and cells treated with the proteasome inhibitor MG132 to identify ubiquitinated proteins
that are targeted to the proteasome for degradation. A number of proteasome substrates were identified.
In addition, the quantitative approach allowed us to compare proteasome targeting by different ubiquitin
chain topologies in vivo. The tools and strategies described here can be applied to detect changes in
ubiquitination dynamics in response to various changes in growth conditions and cellular stress and
will contribute to our understanding of the ubiquitin/proteasome system.
Keywords: HB-ubiquitin • ubiquitin profiling • SILAC • MG132 • tandem affinity purification
Introduction
Ubiquitin is a 76-amino acid protein that is ubiquitously
distributed and highly conserved throughout eukaryotic organ-
isms. Regulation of proteins by post-translational modification
with ubiquitin plays an important role in a variety of cellular
processes including protein degradation, stress response, cell-
cycle regulation, protein trafficking, endocytosis, signaling, and
transcriptional regulation.1,2
The active form of ubiquitin is generated from a high
molecular weight precursor by the action of ubiquitin C-
terminal hydrolases (UCH), which release the mature 8 kDa
protein. After cleavage, ubiquitin exposes glycine 76, which
forms an isopeptide bond with the -amino-group of a lysine
residue of substrate proteins. Ubiquitin conjugates are formed
by the sequential catalytic actions of E1-activating and E2-
conjugating enzymes and E3-ligases. Whereas only two E1-
activating enzymes are involved in the ubiquitination of all
target proteins, distinct E2-conjugating enzymes appear to be
dedicated to the ubiquitination of different substrates. E3-
ligases stimulate E2 conjugation activity and provide protein
target specificity by bridging the substrate/E2 interaction. Like
other posttranslational modifications, ubiquitination is a re-
versible modification due to the function of ubiquitin hydrolases.
The ubiquitin molecule can be found free or conjugated to
protein substrates. When conjugated to substrate proteins one
distinguishes between mono, multi, and poly ubiquitinated
substrates. While the former two describe the linkage of single
ubiquitin molecules to one or more lysine residues in sub-
strates, polyubiquitination involves the formation of ubiquitin
chains, which is achieved by linking additional ubiquitin
molecules to lysine residues in substrate-attached ubiquitin
molecules. All seven internal lysine residues of ubiquitin (K6,
K11, K27, K29, K33, K48, and K63) can in principle be used for
chain formation, and the various resulting ubiquitin chain
topologies have been detected in vivo in yeast and mammalian
cells.3-5
Mono ubiquitination does generally not target proteins to
the proteasome for degradation, but has regulatory functions
that remain to be described at a mechanistic level. However,
the importance of monoubiquitination of histone molecules
in regulation of chromatin structure and the function of mono
and multiubiquitination in receptor down regulation is evident
from physiological studies.6
The most common ubiquitin chain linkage, through
lysine-48, provides primarily a signal for proteolysis by the 26S
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proteasome. In contrast, lysine-63 linked ubiquitin chains are
thought to have signaling function and are not recognized by
the proteasome. The function of other ubiquitin chain topolo-
gies is not known.
Ubiquitination is involved in most if not all cellular pro-
cesses. To obtain a global understanding of the role of ubiq-
uitination, proteome-wide approaches are desirable. Most of
the global strategies have been applied in the model system
yeast,3,5,7-9 but some studies have demonstrated feasibility in
mammalian systems.4,10-13 We describe here the development
of a strategy that utilizes cell lines stably expressing tandem
6xHis-biotin-tagged ubiquitin for purification of the ubiquiti-
nated proteome under fully denaturing conditions. Further-
more, we combined this approach with SILAC-based quanti-
tative mass spectrometry for sensitive detection of changes in
global ubiquitin profiles in response to inhibition of the
proteasome.
Methods
Plasmids, Cloning and Expression of HB-Ubiquitin, Cell
Culture, and Transfections. The retroviral vector pQCXIP (BD
Biosciences) was used to express yeast HB-ubiquitin (pQCXIP-
HB-ubi). Viral particles were generated in 293 GP2 packaging
cells and used to transduce HeLa cells according to standard
protocols in order to establish a stable cell line expressing HB-
ubiquitin. Stable cell lines were periodically maintained with
puromycine for selection.
HeLa cells were cultured in DMEM supplemented with 10%
FCS, 1 µM biotin and 1% antibiotic-antimycotic agent (Invit-
rogen) in 5% CO2 at 37 °C. All cell lines were tested for
mycoplasma contaminations and periodically treated with
plasminogen (InvivoGen, San Diego).
To differentially label MG132 treated and untreated cells
expressing HB-ubiquitin, a SILAC DMEM medium was used
(Thermo Scientific, Rockford, IL), lacking the two essential
amino acids arginine and lysine. Heavy media were supple-
mented with 0.028 mg/mL 13C6
15N4 arginine (isotopic purity
> 98 atom %) and 0.073 mg/mL 13C6
15N2 lysine (isotopic purity
> 98 atom %) (Cambridge Isotope Labeling, Andover, MA) and
the same amount of 12C14N-arg/lys was added to the light
medium.
To inhibit proteasome activity, cells were treated with 10 µM
MG132 (American Peptide, Sunnyvale, CA) for 90 min at 37 °C.
The control cells were treated with the solvent (DMSO) in
parallel.
Tandem Affinity Purification of Ubiquitinated Proteins
from Cell Lysates. Cells were grown in 150 mm dishes (15
plates in experiment 1-3; 20 plates in the SILAC experiments
4 and 5). Cells attached to plates were washed twice with ice
cold 1× PBS, pH 7.4, and harvested on plates with buffer A (8
M urea, 300 mM NaCl, 50 mM NaH2PO4, 0.5% NP-40), pH 8.0,
and 1 mM PMSF.
Lysates were centrifuged at 15 000g, 30 min, 20 °C, and the
clarified supernatant was used for purification. 35 µL of Ni2+
sepharose beads (GE Healthcare) were used for each 1 mg of
protein lysates and were incubated overnight at room temper-
ature in buffer A with 10 mM imidazole on a rocking platform.
Beads were pelleted by centrifugation at 100 × g for 1 min and
washed sequentially with 20 bead volumes of buffer A (pH 8.0),
buffer A (pH 6.3), and buffer A (pH 6.3) with 10 mM imidazole.
After washing the beads, proteins were eluted twice with 5 bead
volumes of buffer B (8 M Urea, 200 mMNaCl, 50 mMNa2HPO4,
2% SDS, 10 mM EDTA, 100 mM Tris, 250 mM imidazole) pH
4.3. The pH of the elute was adjusted to pH 8.0. Ubiquitinated
proteins were bound to 7 µL streptavidin sepharose beads
(Thermo Scientific, Rockford, IL) for each 1 mg of initial protein
lysate by incubation on a rocking platform overnight at room
temperature. Streptavidin beads were washed sequentially with
2 × 25 bead volumes of buffer C (8 M Urea, 200 mM NaCl, 2%
SDS, 100 mM Tris, pH 8.0) and buffer D (8 M Urea, 1.2 M NaCl,
0.2% SDS, 100 mM Tris, 10% EtOH, 10% Isopropanol, pH 8.0).
After washing the beads 3 times with 25 mM NH4HCO3, pH 8,
the proteins were released by on-bead digestion with trypsin
at 37 °C for 12-16 h on a rocking platform as described.5,14
Tryptic peptides were extracted 3 times using 25% (v/v)
acetonitrile (ACN), 0.1% (v/v) formic acid (FA) and subse-
quently separated by strong cation exchange (SCX) chroma-
tography, as previously described.15 Twelve fractions were
manually collected, desalted, concentrated, and analyzed by
LC-MS/MS as described.15
Liquid Chromatography, Tandem Mass Spectrometry,
and Data Processing. LC-MS/MS was carried out by nanoflow
reverse phase liquid chromatography (RPLC) (Eksigent, CA)
coupled online to a Linear Ion Trap (LTQ)-Orbitrap XL mass
spectrometer (Thermo-Electron Corp). Briefly, the LC separa-
tion was performed using a capillary column (100 µm ID ×
150 mm long) packed with C18 resin (GL sciences) and the
peptides were eluted using a linear gradient from 2 to 5% B
over 5 min and 5 to 25% B over 90 min at a flow rate of 350
nL/min (solvent A: 100% H2O/0.1% formic acid; solvent B: 100%
acetonitrile/0.1% formic acid). Nanoelectrospray was achieved
using a pulled capillary tip with 10 µm ID (New Objectives,
Woburn, MA) mounted on a packed tip stand manufactured
by Thermoelectron Corp.; 1.7kV was applied on the tip. A cycle
of one full FT scan mass spectrum (350-2000 m/z, resolution
of 60 000 at m/z 400) was followed by 10 data-dependent MS/
MS acquired in the linear ion trap with normalized collision
energy (setting of 35%). Target ions already selected for MS/
MS were dynamically excluded for 30 s.
Monoisotopic masses of parent ions and corresponding
fragment ions, parent ion charge states and ion intensities from
the tandem mass spectra (MS/MS) were obtained using an in-
house software with Raw_Extract script from Xcalibur v2.4.
Following automated data extraction, resultant peak lists for
each LC-MS/MS experiment were submitted to the develop-
ment version 5.0 of Protein Prospector (UCSF) for database
searching similarly as described.16
A concatenated SwissProt (2007.11.07) database generated
from the normal database and its reversed form (34,972 entries)
was used for database searching. Trypsin was set as the enzyme
with a maximum of two missed cleavage sites. The mass
tolerance for parent ion was set as ( 20 ppm, whereas (1 Da
tolerance was chosen for the fragment ions. Following chemical
modifications were selected as variable modifications during
database search: protein N-terminal acetylation, methionine
oxidation, N-terminal pyroglutamine, and deamidation of
asparagine. Maximal modifications on a given peptide was set
as 3. The Search Compare program in Protein Prospector was
used for summarization, validation and comparison of results.
To determine the expectation value cutoff that corresponds to
a percent false positive (% FP) rate, the plot of the expectation
values versus % FP rate for each search result was automatically
obtained using the Search Compare Program. Based on these
results, we chose an expectation value cutoff for all peptides
corresponding to e1% FP. General protein identification is
based on at least two peptides. For the SILAC samples, two
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additional variable modifications were included: 13C6
15N4-
labeled arginine and 13C6
15N2-labeled lysine.
To quantify protein relative abundance changes, the Search
Compare function was used to determine the light/heavy (L/
H) ratios based on the intensities of the monoisotopic masses
of the parent ion peptide pairs. Search Compare also corrects
for the isotopic purity of the heavy SILAC amino acids, which
was set to 98% purity with the signal/noise threshold set at 10.
The peptide peak intensities were averaged across the elution
profile (30 s) as described.16 For peptides matching to multiple
members of a protein family, only the protein containing at
least one unique peptide was reported. In the case that none
of the proteins contain at least one unique peptide, all of the
possibilities are reported with a “/” separating the protein
names.
After protein identification, a second search was performed
for each sample against the list of proteins identified with the
given cutoff threshold to identified ubiquitination sites. During
the second search, the following variable modifications were
added: carbamylation of lysine, dioxidation of tryptophan,
GlyGly modification of lysine, and phosphorylation of serine,
threonine, or tyrosine.
All peptides with precise ubiquitination sites and ubiquitin
chain linkage types were manually confirmed, considering the
following 4 steps:
1. Each MS/MS spectrum for validation was individually
submitted for a database search, using the Swissprot concan-
tenated database without species restriction.
2. All of the b and y ion series were inspected manually to
ensure the sensible interpretation based on peptide fragmenta-
tion rules (e.g., favorable cleavage at P site).17
3. A series of consecutive y and/or b ions should be observed
and all of the major ions have to be interpreted.
4. MS/MS spectra of modified- and unmodified peptides
have to be compared.
Cell Proliferation Assay. The growth rate of HeLa cells and
HeLa cells expressing HB-tagged ubiquitin was determined by
a colorimetric cytotoxicity assay, which measures the cellular
protein content of cell cultures.18 In brief, cells were fixed with
0.4% trichloroacetic acid (wt/vol) and stained with sulfor-
hodamine B dissolved in 1% acetic acid. The protein bound
dye was extracted with 10 mM Tris base and the optical density
was measured at 564 nm (Figure 1C).
Immunoblot Analysis. Proteins were separated by SDS-
PAGE and transferred to PVDF membranes using a semidry
blotting apparatus. Membranes were blocked in TBS containing
0.2% Tween-20 and 5% milk for 60 min and incubated in
primary antibodies overnight at 4 °C. The RGS4His antibody
(Qiagen, Valencia, CA) for detection of the RGS6xHis tag was
diluted 1:2000 in TBS-Tween-20, 5% milk. HRP-conjugated
secondary antibodies were used at a dilution of 1:15 000 in TBS-
Tween-20, 5% milk. To detect the biotinylated portion of the
HB-tag the membrane was incubated for 1-2 h at room
temperature with HRP-conjugated streptavidin (1:10 000 in
TBS-Tween) (Fisher, Pittsburgh, PA). Immunodetection was
performed with SuperSignal West Pico chemiluminescent
substrate (Pierce, Rockford, IL).
Figure 1. HeLa cells stably expressing HB-tagged ubiquitin. (A) Schematic depiction of the HB-ubiquitin expression construct. The
RGS6xHis epitope combined with a bacterially derived in vivo biotinylation signaling peptide was fused to ubiquitin. Expression was
driven by the CMV type I enhancer and a MSV promoter. The puromycine resistance marker (Purr) was coexpressed using an internal
ribosomal entry site (IRES). (B) Total cell lysates from HeLa cells expressing HB-ubiquitin or no tag were analyzed by Western blotting
using a HRP-streptavidin conjugate to detect the HB-tag. (C) Cell proliferation of HeLaHB-ubi cells and HeLa cells expressing no tag was
compared using a sulforhodamine-B based assay. The median values with standard deviations obtained from 5 independent experiments
are shown.
research articles Meierhofer et al.
4568 Journal of Proteome Research • Vol. 7, No. 10, 2008
Results and Discussion
HeLa Cells Stably Expressing HB-Tagged Ubiquitin. To
detect ubiquitinated proteins in human cells, we fused a
tandem affinity tag to ubiquitin (HB-ubiquitin), and generated
stable cell lines expressing HB-ubiquitin (Figure 1A, 1B). The
HB-tag allows two-step purification under fully denaturing
conditions such as 8 M urea.5,14,19 These stringent conditions
preserve ubiquitination and avoid copurification of proteins
that bind to ubiquitinated proteins but are not ubiquitinated
themselves. Expression of HB-ubiquitin in the stable HeLa cell
line was confirmed by immunoblot analysis with a streptavidin-
HRP conjugate (Figure 1B). A smear pattern typical for ubiq-
uitinated proteins was detected in the total lysates of HB-
ubiquitin expressing HeLa cells (HeLaHB-ubi) but not in control
cell lines without the tagged ubiquitin. Detection of high-
molecular weight ubiquitin signals confirmed previous results
that HB-ubiquitin is functional and is conjugated to proteins.5
The two distinct bands detected in the control cell lines are
endogenous biotinylated proteins (Figure 1B). Expression of
HB-ubiquitin had no effect on the growth rate of HeLa cells,
indicating that HB-tagged ubiquitin does not significantly
interfere with cellular processes regulated by ubiquitination
(Figure 1C). Together these results demonstrate that HB-tagged
ubiquitin is conjugated to other proteins in vivo and expression
of HB-ubiquitin has no obvious adverse effects on cellular
pathways.
Purification and Identification of Ubiquitinated Proteins.
To identify proteins covalently modified with HB-ubiquitin in
mammalian cells, we sequentially purified proteins by Ni2+-
chelate choromatography and binding to streptavidin agarose
as described previously.5 Ubiquitinated proteins were purified
from between 41 and 60 mg of total HeLa cell lysates.
Endogenous biotinylated proteins were eliminated in the first
purification step. Binding to streptavidin beads is virtually
irreversible allowing for stringent wash conditions, but pre-
vented elution of the purified ubiquitinated proteins. Therefore,
samples still bound to streptavidin beads were digested with
trypsin for MS analyses. We followed the purification of
ubiquitinated proteins by immunoblotting using antibodies
against the RGS6His epitope that is part of the HB-tag (Figure
2). Importantly, similar to what has been observed in yeast,5
the HB-tag was quantitatively biotinylated in vivo in HeLa cells
because a very high fraction of proteins carrying the RGS6His
epitope bound to streptavidin agarose indicating that they had
been biotinylated in vivo (Figure 2, compare lanes 4 and 5).
Purified samples were digested “on-bead” with trypsin,
separated by ion exchange chromatography and about 12 -22
fractions were collected and analyzed by LC-MS/MS. Data
were processed using the developmental version of Protein
Prospector at UCSF. Three independent experiments were
performed (experiments 1-3, Supplementary Table 1, Sup-
porting Information). Using a false-positive rate setting of<1%,
we identified 535 potential ubiquitination substrates by at least
two unique peptides in at least two out of three experiments
(Supplementary Table 1, Supporting Information). A total of
669 putative ubiquitinated proteins were identified when we
included proteins identified by a single peptide in at least two
out of the three independent experiments (experiments 1-3
Supplementary Table 1, Supporting Information). Purification
from an equivalent amount of protein lysates prepared from
cells expressing no HB-tagged ubiquitin showed that nonspe-
cifically purified background was very low. Twenty-five proteins
could be clearly identified as background because the number
of identified unique peptides was similar or higher in the
control (untagged ubiquitin) purification as compared to the
HeLaHB-ubi experiment. Sixty-two additional proteins were
identified in both the control experiment and the three
HeLaHB-ubi experiments, indicating that these might be poten-
tial background proteins. However, these 62 proteins were
generally high abundant proteins such as Actin, tubulin,
ribosomal proteins, heatshock proteins, and histones and only
very few peptides were detected in the control purification
whereas substantially more unique peptides were detected in
the HeLaHB-ubi purification. In addition, for a number of them
we could detect ubiquitinated lysine residues, which strongly
suggests that these proteins are genuinely ubiquitinated. We
think that these proteins are likely ubiquitination substrates
and thus included them in the list of ubiquitinated proteins,
but marked them to indicate that they were also detected in
the control purification (Supplementary Table 1, Supporting
Information).
We identified known short-lived proteins that have been
demonstrated to be substrates of the ubiquitin proteasome
system, such as cyclins, cyclin-dependent kinase inhibitors, E3
ubiquitin ligases, the hypoxia-inducible factor 1R (HIF-1R), and
several DNA replication licensing factors (MCM proteins).20,21
In addition, we also identifiedmonoubiquitinated proteins such
as histones, and the Fanconi anemia proteins FANC-D2 and
FANC-I.22,23 Together these results demonstrate that stable cell
lines expressing HB-tagged ubiquitin combined with the
purification and analysis strategy presented here is an effective
Figure 2. Tandem-affinity purification of ubiquitinated proteins
from HeLa cells. Purification efficiency was monitored by im-
muno blotting using an anti-RGS4H antibody directed against
the HB-tag. Protein samples were separated on a 10% SDS-
polyacrylamide gel and processed for immunoblotting. FT: flow-
through.
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approach for system-level identification of a wide-spectrum of
ubiquitination substrates.
Precise Ubiquitin Attachment Sites and Ubiquitin Chain
Topology. In addition to the identification of 669 proteins as
potential ubiquitination substrates we identified 44 precise
ubiquitination sites, based on a 114 Da mass shift due to a
double glycine that remains attached to the modified amino
acid after trypsin cleavage3 (Table 1). Among them are lysines
119 and 121 in histone H2A and H2B, respectively (Figure 3A-
B). These lysine residues in histones have been shown in
directed studies to be monoubiquitinated.24 Furthermore, we
identified lysine 538 in HIF-1R as a ubiquitin attachment site
in vivo (Figure 3C). This lysine residue has previously been
suggested as an ubiquitination site based on mutational
analysis.25 These examples demonstrate that the global strategy
reported here leads to biologically relevant information and
also shows that our approach is efficient enough for identifica-
tion of monoubiquitinated substrates. All identified ubiquitin
attachment sites were lysine residues. We did not detect
ubiquitination of cysteine, or the N-terminal amino group in




ubiquitinated lysine protein name
number
uniquea
P51665 DIK(GlyGly)DTTVGTLSQR K180 26S proteasome non-ATPase
regulatory subunit 7
4
P60866 DTGK(GlyGly)TPVEPEVAIHR K8 40S ribosomal protein S20 3
P23396 FGFPEGSVELYAEK(GlyGly)VATR K90 40S ribosomal protein S3 13
P23396 K(GlyGly)PLPDHVSIVEPK K202 40S ribosomal protein S3 13
P08195 IK(GlyGly)VAEDEAEAAAAAK K46 4F2 cell-surface antigen heavy
chain
17
P27635 FNADEFEDM(Oxidation)VAEK(GlyGly)R K188 60S ribosomal protein L10 6
P36404 LNIWDVGGQK(GlyGly)SLR K71 ADP-ribosylation factor-like
protein 2
3
Q9Y3E7 ILFEITAGALGK(GlyGly)APSK K183 Charged multivesicular body
protein 3
2
Q13619 TNGLT(Phospho)KPAALAAAPAK(GlyGly)PGGAGGSK K33 Cullin-4A 3




O14602 DYQDNK(GlyGly)ADVILK K88 Eukaryotic translation initiation
factor 1A, Y-chromosomal
2
Q13347 VK(GlyGly)GHFGPINSVAFHPDGK K282 Eukaryotic translation initiation
factor 3 subunit 2
7
P62826 FNVWDTAGQEK(GlyGly)FGGLR K71 GTP-binding nuclear protein
Ran
8
P16403 M(Met-loss+Acetyl)SETAPAAPAAAPPAEK(GlyGly)APVK K17 Histone H1.2 8
P04908 VTIAQGGVLPNIQAVLLPK(GlyGly)K K119 Histone H2A type 1-B 11
P23527 AVTK(GlyGly)YTSSK K121 subtype 1-O Histone H2B subtype 16
Q09028 M(Met-loss+Acetyl)ADK(GlyGly)EAAFDDAVEER K4 Histone-binding protein RBBP4 4
Q16576 M(Met-loss+Acetyl)ASK(GlyGly)EMFEDTVEER K4 Histone-binding protein RBBP7 7
Q15047 KS(Phospho)SSQDLHK(GlyGly)GTLSQMSGELSK K182 Histone-lysine
N-methyltransferase SETDB1
11
Q16665 LELVEK(GlyGly)LFAEDTEAK K538 Hypoxia-inducible factor 1 alpha 9
Q01650 ALAAPAAEEK(GlyGly)EEAR K19 Large neutral amino acids
transporter small subunit 1
7
Q01650 M(Oxidation)LAAK(GlyGly)SADGSAPAGEGEGVTLQR K30 Large neutral amino acids
transporter small subunit 1
7
O43684 VAVEYLDPSPEVQK(GlyGly)K K216 Mitotic checkpoint protein BUB3 5
P62937 VSFELFADK(GlyGly)VPK K28 Peptidyl-prolyl cis-trans
isomerase A
6
Q99755 GAIQLGITHTVGSLSTK(GlyGly)PER K103 Phosphatidylinositol-4-phosphate
5-kinase type-1 alpha
6
P07737 TFVNITPAEVGVLVGK(GlyGly)DR K54 Profilin-1 7
P25786 LVSLIGSK(GlyGly)TQIPTQR K115 Proteasome subunit alpha type-1 5
P25786 ETLPAEQDLTTK(GlyGly)NVSIGIVGK K208 Proteasome subunit alpha type-1 5
Q16186 M(Oxidation)SLK(GlyGly)GTTVTPDK K34 ADRM1 4
Q01105 VLSK(Label:13C6
15N2+GlyGly)EFHLNESGDPSSK(Label:13C615N2) K154 SET 3
Q8N0X7 TRPSSDQLK(GlyGly)EASGTDVK K362 Spartin 7




15N4)+GlyGly)AAIVAR(Label:13C615N4) K212 Thioredoxin-interacting protein 4
P51571 VQNM(Oxidation)ALYADVGGK(GlyGly)QFPVTR K73 Translocon-associated protein
subunit delta precursor
4
P68363 VGINYQPPTVVPGGDLAK(GlyGly)VQR K370 subtype 1B Tubulin alpha-subtype 17
P68363 GDVVPK(GlyGly)DVNAAIATIK K326 subtype 1B Tubulin alpha-subtype 17
P07437 ISVYYNEATGGK(GlyGly)YVPR K58 Tubulin beta chain 20
O94888 QEILVEPEPLFGAPK(GlyGly)R K99 UBX domain-containing protein
7
10
P54725 EDK(GlyGly)SPSEESAPTTSPESVSGSVPSSGSSGR K122 UV excision repair protein
RAD23 homologue A
6
O94833 IAT(Phospho)TAEPADKVK(GlyGly)ILK K3058 Bullous pemphigoid antigen 1,
isoforms 6/9/10
P07437 M(Oxidation)SM(Oxidation)K(GlyGly)EVDEQM(Oxidation)LNVQNK K324 Tubulin beta chain
P15531 VM(Oxidation)LGETNPADSK(Label:13C6
15N2)+GlyGly)PGTIR(Label:13C615N4) K100 Nucleoside diphosphate kinase
A/kinase B
P55061 K(GlyGly)INFDALLK K7 Bax inhibitor 1
P63092 QDLLAEK(GlyGly)VLAGK K360 Guanine nucleotide-binding
protein G(s) subunit alpha
isoforms short
P67809 GAEAANVTGPGGVPVQGSK(GlyGly)YAADR K137 Nuclease sensitive
element-binding protein 1
a Number of unique peptides identified for each protein. MS/MS spectra for each reported peptide can be found in Supplementary Figure 1
(Supporting Information).
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this global approach, which has been reported for selected
proteins and in the case of cysteine residues could have been
detected as an activated thioester intermediate on E1, E2, or
HECT domain E3s.26-29
Precise ubiquitin attachment sites are based on a double
glycine remnant linked to lysine after trypsin digestion. Similar
double glycine remnants are indicative for modification with
the ubiquitin-like protein Nedd8.30 This mass spectrometric
Figure 3. Ubiquitin acceptor lysines. MS/MS spectra of tryptic peptides containing Gly/Gly linked to lysine. (A) Histone H2A; MH3
3+
725.11; VTIAQGGVLPNIQAVLLPK(GlyGly)K+3. (B) Histone H2B; MH2
2+ 549.79; AVTK(GlyGly)YTSSK+2. (C) Hypoxia- inducible factor 1
alpha; MH3
3+ 619.99; LELVEK(GlyGly)LFAEDTEAK+3.
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strategy can thus not differentiate between neddylation and
ubiquitination sites. However, because we analyzed samples
enriched for ubiquitinated proteins, the lysine residues pre-
sented in Table 1 are most likely ubiquitination sites.
Ubiquitin chains are formed by isopeptide links between the
C-terminal carboxyl group of one ubiquitin molecule with any
of seven lysine residues in another ubiquitin molecule. De-
pending on the ubiquitin chain architecture the chain can send
different biological signals. Our global analyses found in vivo
evidence for ubiquitin chain linkages through any of the seven
possible lysine residues in ubiquitin (Table 2). Similar results
have been reported in yeast and to some extend in mammalian
cells.3-5,13
Finally, we asked whether ubiquitination targets are enriched
in any biological processes. Using the data reported in Supple-
mental Table 1 (Supporting Information), we found that
ubiquitinated proteins were significantly overrepresented in
several categories including expected processes like proteolysis,
cell cycle, mitosis, chromatin packaging, chromosome segrega-
tion and protein metabolism (Figure 4).
Quantitative Analysis of Ubiquitinated Proteins in Re-
sponse to Proteasome Inhibition. We aimed to apply the
strategy outlined above to detect quantitative differences in
global ubiquitination profiles in response to perturbation of
normal cellular function. We chose to analyze changes in
ubiquitination profiles in response to inhibition of 20S pro-
teasome activity using the proteasome inhibitor MG132. We
expected to observe significant shifts in ubiquitination profiles
upon inhibition of proteasome activity because marking pro-
teins for proteasomal degradation is one of the major roles for
protein ubiquitination. In addition, we were interested to
identify ubiquitinated proteins where ubiquitination does not
target for degradation by the proteasome but presents a
different signal. To identify quantitative changes in global
ubiquitination patterns we used the SILAC strategy31-33 and
labeled all proteins with heavy lysine and arginine. Cells grown
in heavy medium were treated with 10 µM MG132 for 90 min
prior to cell lysis and cells in light medium were mock treated
with DMSO. To exclude effects of supplementation with heavy
lysine and arginine and to evaluate reproducibility of this
quantitative approach we performed a label-switch experiment
where proteasome inhibitor was added to cells grown in light
medium and cells grown in heavy medium where mock-
treated.
Twenty-three milligrams and 39 mg of total cell lysates (experi-
ment 4 and 5 in Supplementary Table 2), respectively, were
analyzed. Light and heavy lysates for each experiment weremixed
in a 1:1 ratio after cell lysis. Ubiquitinated proteins were tandem-
affinity purified and analyzed as described above.
Using a false-positive rate setting of <1% we identified 381
proteins (191 proteins with at least two unique peptides) in
experiment 4, and 362 proteins (187 proteins with at least two
unique peptides) in experiment 5 (label switch experiment).
The complete lists with all proteins can be found in Supple-
Table 2. Representative Peptides of Identified Ubiquitin-Chain Linkages by LC-MS/MSa
position of
ubiquitinated lysine peptide sequence m/z (observed) expectation value39
K6 MQIFVK(GlyGly)TLTGK 690.3899 2.50E-02
K11 TLTGK(GlyGly)TITLEVEPSDTIENVK 1201.6399 8.80E-06
K27 TITLEVEPSDTIENVK(GlyGly)AK 701.0390 1.40E-03
K29 AK(GlyGly)IQDK(Carbamyl)EGIPPDQQR 940.4865 2.00E-02
K33 IQDK(GlyGly)EGIPPDQQR 819.4203 1.70E-04
K48 LIFAGK(GlyGly)QLEDGR 730.9002 3.20E-05
K63 TLSDYNIQK(GlyGly)ESTLHLVLR 1122.6052 7.40E-06
a MS/MS spectra for each reported peptide can be found in the Supplementary Figure 2 (Supporting Information).
Figure 4. Biological process analysis. Analysis was performed with the online software PANTHER (http://www.pantherdb.org/tools),
using the data set reported in Supplementary Table 1 (Supporting Information). The p value was set to >0.05, the Bonferroni correction
for multiple testing’s was used. Only categories with significant differences are shown.
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mentary Table 2 (Supporting Information); 230 proteins were
identified in both experiments and were used for quantitative
comparison.
We next determined the relative abundance changes induced
by proteasome inhibition. Light to heavy (L/H) ratios were
determined for all proteins with at least one high-quality,
quantifiable peptide detected in both experiments. The recip-
rocal L/H value was calculated for experiment 5. L/H ratios
over 5-fold and under 0.2-fold were set to 5 and 0.2, because
peak height measurements for the low abundant peptide
partner in the pairs was no longer reliable. Following these
criteria we detected 220 ubiquitinated proteins, 51 of them were
up-regulated and 15 down-regulated in response to MG132
treatment considering a ratio between 0.75 and 1.33 as neither
significantly up- or down-regulated. 97% of the proteins
identified in experiment 4 and 5 were also identified as
ubiquitination substrates in experiments 1 to 3, which were
performed without proteasome inhibition. (Supplementary
Tables 1 and 2, Supporting Information).
L/H ratios were visualized in a log-log plot to the base 2
(Figure 5). As expected, quantitation showed an increase in the
abundance of many ubiquitinated proteins in response to
proteasome inhibition. Surprisingly, a significant number of
proteins showed a highly reproducible decrease in the ubiq-
uitinated form in response to MG132 treatment. Among them
were various histones. For example, histone H2A.Z had a L/H
ratio of 2.7 in experiment 4 (MG132 added to the heavy sample)
and a matching reciprocal L/H ratio of 0.38 in experiment 5
(MG132 in the light sample). This phenomenon can be
explained by the fact that most of the cellular ubiquitin is
trapped in ubiquitin chains upon proteasome inhibition, which
has been proposed to cause ubiquitin stress and induction of
release of ubiquitin from ubiquitinated histones.34,35 Our
quantitative analyses of proteome-wide ubiquitination is in
agreement with the model of redistribution of cellular ubiquitin
pools.
The HB-ubiquitin expressed in HeLa cells was derived from
the budding yeast UBI4 gene, which encodes for ubiquitin that
differs at three positions from human ubiquitin. Two of the
three amino acid changes are located on a single tryptic peptide
and thus allowed us to distinguish between HB-tagged ubiq-
uitin and the endogenous untagged human ubiquitin. The third
amino acid change affects position 28, which is flanked by
lysine residues and the corresponding tryptic peptide could not
be detected. As expected, the HB-ubiquitin specific L/H peptide
ratios were close to 1 (Table 3), demonstrating that neither
purification efficiency nor HB-ubiquitin expression was affected
by treatment with MG132. The human-specific tryptic ubiquitin
peptide was used to quantify the increase of ubiquitin chains
after inhibition of the proteasome because the untagged
ubiquitin will only be purified when it is part of an ubiquitin
chain that also contains HB-ubiquitin. Based on the L/H ratios
for the human-specific ubiquitin peptide we can therefore
conclude that the abundance of ubiquitin chains increased 3
fold in response to MG132 treatment (Table 3). The vast
majority of tryptic ubiquitin peptides do not allow to differenti-
ate between HB-ubiquitin and endogenous ubiquitin. The L/H
rations for these peptides were 2.24, which is significantly lower
than the 3-fold increase measured for total ubiquitin chains.
This reduced ratio observed for peptides that cannot distinguish
between the tagged and the endogenous ubiquitin is due to
the fraction of tagged ubiquitin incorporated into chains
because the L/H ratio of HB-ubiquitin remains at 1, even after
proteasome inhibition (table 3). We can thus use the differences
in L/H ratios obtained for human-specific and for general
ubiquitin peptides to calculate that HB-ubiquitin was expressed
at about 38% of the endogenous ubiquitin levels in these cell
lines. Immunoblot analyses were consistent with these results
suggesting a 2-fold excess of endogenous ubiquitin over HB-
ubiquitin.
Quantitative Analysis of Ubiquitin Chain Topologies. We
next asked how the different ubiquitin chain topologies con-
tribute to the overall increase in ubiquitin chains after protea-
some inhibition.
We determined L/H ratios of the signature peptides for K6,
K11, K27, K33, K48, and K63 ubiquitin/ubiquitin linkages
(Figure 6, table 3). The reciprocal values from the label-switch
experiment were almost identical suggesting that the observed
changes in these ubiquitin chain types in response to protea-
Figure 5. Abundance changes of ubiquitinated proteins in re-
sponse to proteasome inhibition. SILAC ratios of identified
ubiquitinated proteins from two independent experiments are
compared on a log-log plot to the base 2. Each black square
represents a single protein. The dotted line indicates the position
of exact matching data points from both experiments.
Table 3. L/H Peptide Ratios for the HB-Tag, Ubiquitin, and
Specific Ubiquitin-Chain Typesa






HB-tag 0.99 0.20 (n ) 1368) 0.99 0.13 (n ) 1611)
yeast ubiquitin 0.96 0.05 (n ) 394) 0.99 0.04 (n ) 307)
human ubiquitin 3.08 0.35 (n ) 196) 0.34 0.05 (n ) 269)
other ubiquitin 2.24 0.38 (n ) 220) 0.37 0.10 (n ) 472)
K6 2.92 n/a 0.21 n/a
K11 2.82 n/a 0.34 n/a
K27 6.12 n/a 0.24 n/a
K33 4.35 n/a 0.20 n/a
K48 2.43 n/a 0.42 n/a
K63 1.74 n/a 0.64 n/a
a n/a ) not available.
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some inhibition were specific and highly reproducible. We did
not detect signature peptides for K29 chains that could be
quantitated in both experiments to generate data for these
linkage types. Surprisingly, all six types of ubiquitin chains that
could be analyzed increased in response to proteasome inhibi-
tion (Figure 6, Table 3). The K63 linkage showed the smallest
increase consistent with its proteasome-independent functions.
Nevertheless, the 1.7-fold increase demonstrates that at least
some proteins containing K63 chains are degraded. These
experiments cannot determine the context of the detected
linkage types and it is possible that proteins contain mixed
chain topologies, which has been proposed from in vitro
studies.36 In agreement with our global studies, K11, K48, and
K63 ubiquitin chains have previously been reported to increase
in response to proteasome inhibition in mammalian cells.11
K48 chains represent the most abundant chain topology3 and
consistent with it being the predominant chain linkage, the K48
linkage increased at approximately the same level as total
ubiquitin chains did in response to MG132 treatment (Figure
6, Table 3).
Unexpectedly, K6, K11, K27, and K33 were significantly more
up-regulated after MG132 treatment than other chains (Figure
6, Table 3), suggesting that these chains are either part of or
represent very active proteasome targeting signals. Consistent
with this result, K11 linked chains have recently been impli-
cated in APC-controlled degradation of cell cycle regulators.37
Figure 6. Quantitative comparison of ubiquitin chain topologies after proteasome inhibition. MS spectra of peptide pairs characteristic
for ubiquitin chain topologies as indicated. Light/heavy ratios (L/H) were determined using the Search Compare function of Protein
Prospector. The peptide peak intensities were averaged across the elution profile (30 s). Ubiquitin linkage types: (A) K6;MH2
2+ 698.41;
MQIFVK (Label: 13C6
15N2+GlyGly)TLTGK (Label: 13C615N2)+2. (B) K11;MH33+ 806.77; TLTGK (Label: 13C615N2+GlyGly) TITLEVEPSDTIENVK
(Label: 13C6
15N2)
+3. (C) K27; MH3
3+ 706.39; TITLEVEPSDTIENVK(Label:13C6
15N2+GlyGly)AK (Label: 13C615N2)+3. (D) K33; MH22+ 828.43;
IQDK (Label: 13C6
15N2+GlyGly) EGIPPDQQR (Label: 13C615N4)+2. (E) K48;MH22+ 739.91; LIFAGK (Label: 13C615N2+GlyGly) QLEDGR (Label:
13C6
15N4)
+2. (F) K63; MH3
3+ 754.75; TLSDYNIQK (Label: 13C6
15N2+GlyGly) ESTLHLVLR (Label: 13C615N4)
+3.
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Quantitation of chain topologies and their changes in
response to proteasome inhibition suggested that all chain
types are either themselves degradation signals or that they
are present in mixed chains that signal degradation. An
alternative, although in our opinion unlikely interpretation is
that a substrate is modified by two distinct types of chains and
only one of them signals degradation. One also needs to
consider that ubiquitin chain steady state levels are determined
by both protein degradation and deubiquitination. Because
proteasome inhibition significantly increases the total chains
in the cell, an overall reduction of deubiquitination by substrate
competition could occur under these conditions. Nevertheless,
K48 chains are the canonical degradation signals and their
observed 2.7 fold accumulation in response to MG132 treat-
ment suggests that L/H ratios above this value are strong
indicators for proteasome targeting functions. Our results
therefore suggest that K6, K11, K27, K33, and K48 are part of
proteasome targeting signals in mammalian cells. We could not
reliably determine K29 chains in these experiments. This is
probably due to technical issues, because tryptic digestion
releases only a very short peptide for the K29 linkage type.
Results from yeast demonstrated that only K48 and K29 chains
accumulated upon proteasome inhibition,38 suggesting differ-
ences in proteasome signals between yeast and mammals.
Together, the quantitative analysis demonstrated that our
approach can reproducibly describe changes in ubiquitination
dynamics in response to cellular processes and should be a
useful tool to probe various aspects of ubiquitin biology.
Conclusions
We have developed stable cell lines expressing HB-tagged
ubiquitin and a purification strategy for system-level ap-
proaches to ubiquitination in mammalian cells. We applied this
approach to identify proteins covalently modified with ubiq-
uitin and demonstrated sensitivity by identification of 669
potential ubiquitination substrates as well as several precise
ubiquitin attachment sites. Combination of proteome-wide
ubiquitin profiling with SILAC-based quantitative mass spec-
trometry provided insight into ubiquitin-profile changes in
response to proteasome inhibition and the role of individual
ubiquitin chain topologies in proteasome targeting. The tools
and approaches presented here can generally be applied to
study the dynamics of the ubiquitin system in response to
perturbation of cellular pathways or in response to extracellular
signals.
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